Triazoloamides as potent γ-secretase modulators with reduced hERG liability

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 9, 2012, Pages 3140-3146

  Fischer, Christian ^a   Zultanski, Susan L ^a   Zhou, Hua ^a   Methot, Joey L ^a   Shah, Sanjiv ^a   Nuthall, Hugh ^a   Hughes, Bethany L ^a   Smotrov, Nadja ^a   Hill, Armetta ^a   Szewczak, Alexander A ^a   Moxham, Christopher M ^a   Bays, Nathan ^a   Middleton, Richard E ^a   Munoz, Benito ^a   Shearman, Mark S ^a  

^a Merck Research Laboratories Boston   (United States)

Author keywords

Alzheimer's; Amyloid beta; Gamma secretase modulator

Indexed keywords

AMIDE; AMYLOID BETA PROTEIN[1-40]; GAMMA SECRETASE; LACTAM; NOTCH RECEPTOR; POTASSIUM CHANNEL HERG; TRIAZOLE DERIVATIVE; TRIAZOLOAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BINDING AFFINITY; DRUG SYNTHESIS; HYDROPHOBICITY; ISOMERISM; LIPOPHILICITY; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

AMIDES; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; LACTAMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS; TRIAZOLES;

EID: 84859839008     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.03.054     Document Type: Article

References (37)

1. Alzheimer's Association: 2010 Alzheimer's disease facts and figures http://www.alz.org/national/documents/report-alzfactsfigures2010.pdf.
2. G. Thinakara, and E.H. Koo J. Biol. Chem. 283 2008 29615
3. H. Li, M.S. Wolfe, and D.J. Selkoe Cell Struct. 17 2009 326
4. P. Osenkowski, H. Li, W. Ye, D. Li, L. Aeschbach, P.C. Fraering, M.S. Wolfe, D.J. Selkoe, and H. Li J. Mol. Biol. 385 2009 642
5. For example: D.J. Selkoe, and M.S. Wolfe Cell 131 2007 215
6. M.S. Wolfe Curr. Top. Med. Chem. 8 2008 2
7. H. Steiner, R. Fluhrer, and C. Haass J. Biol. Chem. 283 2008 29627
8. M.S. Wolfe Semin. Cell Dev. Biol. 20 2009 219
9. For example: L.W. Hung, G.D. Ciccotosto, E. Giannakis, D.J. Tew, K. Perez, C.L. Masters, R. Cappai, J.D. Wade, and K.J. Barnham J. Neurosci. 28 2008 11950
10. H. Moreno, E. Yu, G. Pigino, A.I. Hernandez, N. Kim, J.E. Moreira, M. Sugimori, and R.R. Llinas PNAS 106 2009 5901
11. D. Abramowski, S. Rabe, A.R. Upadhaya, J. Reichwald, S. Danner, D. Staab, E. Capetillo-Zarate, H. Yamaguchi, T.C. Saido, K.-H. Wiederhold, D.R. Thal, and M. Staufenbiel J. Neurosci. 32 2012 1273
12. For a recent review on secretase biology and modes of γ-secretase inhibition/modulation, see: B. De Strooper, R. Vassar, and T. Golde Nat. Rev. Neurol. 6 2010 99
13. For selected reviews on GSMs, see: I. Peretto, and E. La Porta Curr. Top. Med. Chem. 8 2008 38
14. D. Breher Curr. Top. Med. Chem. 8 2008 34
15. B.P. Imbimbo Curr. Top. Med. Chem. 8 2008 54
16. T. Tomita Expert Rev. Neurother. 9 2009 661
17. For a recent comprehensive review of the GSM chemical space, see: D. Oehlrich, D.J.-C. Berthelot, and H.J.M. Gijsen J. Med. Chem. 54 2011 669
18. For patents in this area, see: Hannam, J. C.; Hartmann, S.; Andrew; R.M.; Mark P. WO2007110667.
19. Madin, A.; Ridgill, M. P.; Kulagowski, J. J. WO 2007116228.
20. Garcia, Y.; Hannam, J. C.; Harrison, T.; Hamblett, C. L.; Hubbs, J. L.; Kulagowski, J. J.; Madin, A.; Ridgill, M. P.; Seward, E. WO 2007125364.
21. Stanton, M. G.; Munoz, B.; Sloman, D. L.; Hubbs, J. L.; Hamblett, C. L. WO 2008030391.
22. Munoz, B.; Hubbs, J. L.; Hamblett, C. L.; Zhou, H.; Martinez, M. WO 2008085301.
23. For a recent comparison with GSIs, see also: Y. Mitani, J. Yarimizu, K. Saita, H. Uchino, H. Akashiba, Y. Shitaka, K. Ni, and N. Matsuoka J. Neurosci. 32 2012 2037
24. For a key patent, see: Kimura, T.; Kawano, K.; Doi, E.; Kitazawa, N.; Shin, K.; Miyagawa, T.; Kaneko, T.; Ito, K.; Takaishi, M.; Sasaki, T.; Hagiwara, H. WO 2005115990.
25. Blurton, P.; Fletcher, S.; Teall, M.; Harrison, T.; Munoz, B.; Rivkin, A.; Hamblett, C.; Siliphaivanh, P.; Otte, K. WO 2008099210.
26. Rivkin, A.; Ahearn, S. P.; Chichetti, S. M.; Hamblett, C. L.; Garcia, Y.; Martinez, M.; Munoz, B. WO 2010019392.
27. A. Rivkin, S.P. Ahearn, S.M. Chichetti, Y.R. Kim, C. Li, A. Rosenau, S.D. Kattar, J. Jung, S. Shah, B.L. Hughes, J.L. Crispino, R.E. Middleton, A.A. Szewczak, B. Munoz, and M.S. Shearman Bioorg. Med. Chem. Lett. 20 2010 1269
28. A. Rivkin, S.P. Ahearn, S.M. Chichetti, C.L. Hamblett, Y. Garcia, M. Martinez, J.L. Hubbs, M.H. Reutershan, M.H. Daniels, P. Siliphaivanh, K.M. Otte, C. Li, A. Rosenau, L.M. Surdi, J. Jung, B.L. Hughes, J.L. Crispino, G.N. Nikov, R.E. Middleton, C.M. Moxham, A.A. Szewczak, S. Shah, L.Y. Moy, C.M. Kenific, F. Tanga, J.C. Cruz, P. Andrade, M.H. Angagaw, N.H. Shomer, T. Miller, B. Munoz, and M.S. Shearman Bioorg. Med. Chem. Lett. 20 2010 2279
29. C. Fischer, S. Shah, B.L. Hughes, G.N. Nikov, J.L. Crispino, R.E. Middleton, A.A. Szewczak, B. Munoz, and M.S. Shearman Bioorg. Med. Chem. Lett. 21 2011 773
30. Fischer, C.; Munoz, B.; Zultanski, S.; Methot, J.; Zhou, H.; Brown, W. C. WO2008156580.
31. C. Fischer, S.L. Zultanski, H. Zhou, J.L. Methot, W.C. Brown, D.M. Mampreian, A.J. Schell, S. Shah, H. Nuthall, B.L. Hughes, N. Smotrov, C.M. Kenific, J.C. Cruz, D. Walker, M. Bouthillette, G.N. Nikov, D.F. Savage, V.V. Jeliazkova-Mecheva, D. Diaz, A.A. Szewczak, N. Bays, R.E. Middleton, B. Munoz, and M.S. Shearman Bioorg. Med. Chem. Lett. 21 2011 4087
32. For a review on click chemistry, see for example: H.C. Kolb, M.G. Finn, and K.B. Sharpless Angew. Chem., Int. Ed. 2001 2004 40
33. 50 measurements for Aβ40 and Aβ42 were determined using electrochemiluminescent detection of peptides secreted by SH-SY5Y cells stably overexpressing the β-APP C-terminal fragment SPA4CT. All compounds were tested at least twice in independent experiments. Consistent with the profile of γ-secretase modulators, total Aβ peptide levels were constant; selected GSMs were confirmed in a SELDI experiment confirming the appearance of shorter fragments while Aβ42 formation was suppressed. (a) Best, J. D.; Jay, M. T.; Otu, F.; Ma, J.; Nadin, A.; Ellis, S.; Lewis, H. D.; Pattison, C.; Reilly, M.; Harrison, T.; Shearman, M. S.; Williamson, T. L.; Atack, J. R. J. Pharm. Exp. Ther. 2005, 313, 902; (b)
34. Clarke, E. E.; Shearman, M. S. J. Neurosci. Methods 2000, 102, 61;
35. (c) Dyrks, T.; Dyrks, E.; Monning, U.; Urmoneit, B.; Turner, J.; Beyreuther, K. FEBS Lett. 1993, 335, 89.
36. All compounds were also profiled at least twice in independent experiments to assess their effect on Notch processing: HeLa cells were made to co-express nonfunctional halves of luciferase, one fused to NotchΔE and the other to RBP-Jκ. γ-Secretase mediated cleavage of NotchΔE results in release of Notch intracellular domain (NICD)/N-terminal luciferase, which translocates to the nucleus and binds the RBP-Jκ/C-terminal luciferase to form a functional luciferase enzyme. This split-luciferase complementation system is used to detect NICD levels by measuring total luminescence upon addition of luciferin to lysed cells. Paulmurugan, R.; Gambhir, S. S. Anal. Chem. 2005, 77, 1295. Typical transition-state analogues (e.g., L-685,458) do not show a window over Aβ 40/42 processing in this assay.
37. For a description of the MK-499/hERG radioligand displacement assay, see: Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.; Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo, D. G. WO 200205860.